Four things to know:
1. The first patient implant was completed by spine surgeon Todd Lanman, MD; 263 patients were enrolled in the study.
2. The FDA is conducting a U.S. Investigational Device Exemption study to compare the M6-C artificial disc and the anterior cervical discectomy and fusion for treating two-level symptomatic cervical radiculopathy.
3. Dr. Lanman said: “The M6-C artificial cervical disc two-level study will provide additional data to validate the effectiveness of disc replacement over fusion in patients suffering from degeneration in two contiguous levels.”
4. Previous long-term studies have shown patients who received the M6-C in an artificial cervical disc single-level clinical trial “continue to have statistically significant benefits at three and four years” compared to anterior cervical discectomy and fusion patients.”
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
